Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Sanofi stops development of Nurix-partnered immune drug

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 4 November →